ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Journal of Clinical Oncology · 20.11.2023 · 41 (33) · 5107-5117
DOI: 10.1200/jco.23.00775 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2023. Verfasst von Pier Luigi Zinzani und 25 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli" and Dipartimento di Scienze Mediche e Chirurgiche, Università d…. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Piperidines, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Deep and durable responses with zanubrutinib plus obinutuzumab in patients with R/R FL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli" and Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
- Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital, Brno, Czech Republic.
- Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX.
- Institut Bergonié, Bordeaux, France.
- Institut Catala d'Oncologia (ICO) Hospital Duran I Reynals, Hospital, Barcelana, Spain.
- Peking University Cancer Hospital and Institute, Beijing, China.
ORCID-Profile: Pier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, Fontanet Bijou, Ana C De Oliveira, Qingyuan Zhang, Michele Merli, Alejandro Martín García-Sancho, Mariano Provencio Pulla, Marek Trněný, Herve Tilly, Sarit E Assouline, Rebecca Auer, Judith Trotman
Zitieren
APA
Zinzani, P. L., Mayer, J., Flowers, C. R., Bijou, F., De Oliveira, A. C., Song, Y., Zhang, Q., Merli, M., Bouabdallah, K., Ganly, P., Zhang, H., Johnson, R., Martín García-Sancho, A., Provencio Pulla, M., Trněný, M., Yuen, S., Tilly, H., Kingsley, E., Tumyan, G., …, & Trotman, J. (2023). ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. Journal of Clinical Oncology, 41(33), 5107-5117. https://doi.org/10.1200/jco.23.00775
Vancouver
Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, et al. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. Journal of Clinical Oncology. 2023;41(33):5107-5117. doi:10.1200/jco.23.00775
BibTeX
@article{Zinzani2023,
author = {Zinzani, Pier Luigi and Mayer, Jiří and Flowers, Christopher R and Bijou, Fontanet and De Oliveira, Ana C and Song, Yuqin and Zhang, Qingyuan and Merli, Michele and Bouabdallah, Krimo and Ganly, Peter and Zhang, Huilai and Johnson, Roderick and Martín García-Sancho, Alejandro and Provencio Pulla, Mariano and Trněný, Marek and Yuen, Sam and Tilly, Herve and Kingsley, Edwin and Tumyan, Gayane and Assouline, Sarit E and Auer, Rebecca and Ivanova, Elena and Kim, Pil and Huang, Sha and Delarue, Richard and Trotman, Judith},
title = {ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {33},
pages = {5107--5117},
doi = {10.1200/jco.23.00775}
}
EUVIMED